PhRMA Wary Of Large Simple Safety Trials, Tells FDA Not To Create Phase III+
Executive Summary
Large simple safety studies should not become a routine pre-approval requirement, the Pharmaceutical Research & Manufacturers of America suggested during FDA's risk management public workshop April 9